- Report
- March 2025
- 190 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 186 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- September 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- March 2025
- 196 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- August 2024
- 140 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- June 2024
- 200 Pages
Global
From €4749EUR$4,995USD£3,989GBP
- Report
- April 2024
- 45 Pages
Global
From €9502EUR$9,995USD£7,982GBP
- Report
- October 2024
- 182 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 276 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- November 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- September 2024
- 143 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- May 2024
- 133 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 137 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- October 2024
- 210 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- May 2024
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP

The Anti Rheumatic market is a subset of the Immune Disorders Drugs market, which focuses on the treatment of rheumatic diseases. These diseases are caused by an abnormal immune response, which can lead to inflammation and joint pain. Anti Rheumatic drugs are used to reduce inflammation and pain, as well as to prevent further damage to the joints. These drugs can be administered orally, intravenously, or topically. Commonly used Anti Rheumatic drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers.
Some companies in the Anti Rheumatic market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more